Effectiveness and safety of nab- paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.

Liangliang Wang; Shuangying Li; Da Zhu; Yu Qin; Xiaoli Wang; Zhenya Hong; Zhiqiang Han

Objective: To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first- line chemotherapy for ovarian cancer (OC). Methods: Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression- free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed. Results: Seventy-two patients (median age, 54.5 years; range, 20.0–79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0–29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9– 30.5) months vs. 30.1 (95% CI=23.1–37.1) months in the primary surgery subgroup. Twenty- seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]–NA) months. The commonest grade 3–4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred. Conclusion: Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.

CANCER chemotherapy; OVARIAN cancer; LEUKOCYTES; PLATINUM; NEOADJUVANT chemotherapy

Journal of Gynecologic Oncology, 2023, Vol 34, Issue 4, p1

2005-0380

Academic Journal

10.3802/jgo.2023.34.e44